Press Release | Newsroom | Medtronic | Form 8.1 – Covidien

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Form 8.1 – Covidien

DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 8, 2014--

FORM 8.1(a)&(b)(i)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

         
Name of person dealing (Note 1)       Covidien plc
Company dealt in       Covidien plc
Class of relevant security to which the dealings being disclosed relate (Note 2)       Ordinary Shares
Date of dealing       5 Sept 2014 and 26 Sept 2014
     

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

                 
        Long       Short
        Number   (%)       Number   (%)
(1) Relevant securities       N/A – Covidien plc only holds treasury shares        
(2) Derivatives (other than options)                
(3) Options and agreements to purchase/sell                
Total                
           

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

                 
Class of relevant security:       Long       Short
        Number   (%)       Number   (%)
(1) Relevant securities                

(2) Derivatives (other than options)

               

(3) Options and agreements to purchase/sell

               
Total                
           

3. DEALINGS (Note 4)

(a) Purchases and sales

                 
Purchase/sale       Number of relevant securities       Price per unit (Note 5)
Purchase (Redemption to Treasury)       26       US$88.08
Purchase (Redemption to Treasury)       223       US$89.98
           

(b) Derivatives transactions (other than options transactions)

                         
Product name,

e.g. CFD

      Nature of transaction

(Note 6)

      Number of relevant securities

(Note 7)

      Price per unit

(Note 5)

                         
                 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

                                                 

Product name,
e.g. call option

 

     

Writing, selling,
purchasing,
varying etc.

     

Number of securities
to which the option
relates (Note 7)

     

Exercise
price

     

Type, e.g.
American,
European etc.

     

Expiry
date

     

Option money
paid/received
per unit (Note 5)

                                                 
                                   

(ii) Exercising

                 
Product name,

e.g. call option

      Number of securities      

Exercise price per
unit (Note 5)

                 
           

(d) Other dealings (including transactions in respect of new securities) (Note 4)

                 
Nature of transaction

(Note 8)

      Details      

Price per unit
(if applicable) (Note 5)

 

                 
           

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
 

Is a Supplemental Form 8 attached? (Note 9) NO

         
Date of disclosure       8 October 2014
Contact name       Lisa Clemence
Telephone number       +1 508-452-4375
Name of offeree/offeror with which acting in concert        
Specify category and nature of acting in concert status        
     

A person interested in 1% or more of any relevant securities in the Covidien plc (the “Company”) may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules. This requirement will continue until the offer period ends.

The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Source: Covidien

Covidien
Peter Lucht, 508-452-4168
Vice President
External Communications
peter.lucht@covidien.com
or
Lisa Clemence, 508-452-4375
Director
Corporate Communications
lisa.clemence@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com

X